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Endemic pemphigus foliaceus, like the sporadic form
seen in the developed world, is mediated by IgG anti-
bodies to desmoglein-1. We studied an endemic focus
in Limao Verde, Brazil, where disease prevalence is
3.4%.We previously detected IgG antibodies to desmo-
glein-1 in 97% of patients, but also in 55% of normal
subjects in the endemic focus, with progressively lower
levels in normal subjects in surrounding areas. An en-
vironmental trigger is hypothesized to explain these
and other ¢ndings. In this study we sought to deter-
mine if patients and enzyme-linked-immunosorbent-
assay-positive normal subjects in Limao Verde di¡er in
IgG subclass response to desmoglein-1.We developed a
sensitive and speci¢c subclass enzyme-linked immuno-
sorbent assay using recombinant desmoglein-1 and
standardized the assay to enable comparability between
the four subclasses.We found that normal subjects have
an IgG1 and IgG4 response, whereas patients have simi-
lar levels of IgG1 but a mean 19.3-fold higher IgG4
response. Patients in remission have a weak IgG4
response, and a 74.3-fold higher IgG4 response is asso-
ciated with active disease. Finally, in ¢ve patients in
whom we had blood samples from both before and
after the onset of clinical disease, a mean 103.08-fold rise
in IgG4 was associated with onset of clinical disease, but
only a mean 3.45-fold rise in IgG1. These results suggest
that the early antibody response in normal subjects liv-
ing in the endemic area and in patients before the onset
of clinical disease is mainly IgG1. Acquisition of an IgG4
response is a key step in the development of clinical
disease. Key words: autoantibodies/autoimmunity/desmoglein/
fogo selvagem/IgG4. J Invest Dermatol 120:000 ^000, 2003
E
ndemic pemphigus foliaceus is found mainly in rural
areas in Brazil (Diaz et al, 1989a; 1989b) as well as in
Colombia and Tunisia (Robledo et al, 1988; Morini
et al, 1993). Like the sporadic form seen in the deve-
loped world, it is mediated by IgG antibodies to des-
moglein-1 (dsg1), an epidermal adhesion molecule (Stanley et al,
1986). Antibody binding leads to loss of intercellular adhesion
and subsequent blister formation. A⁄nity-puri¢ed antibodies to
dsg1 have been shown to mediate disease when passively trans-
ferred into mice (Ding et al, 1999), and preabsorption of antidsg1
antibodies has been shown to prevent disease in the mouse model
(Amagai et al, 1995).
We have recently identi¢ed a new focus of endemic pemphigus
foliaceus in Limao Verde, Brazil, where the prevalence of disease
is 3.4% (a total of 31 patients in a population of 916) (Hans-Filho
et al, 1996). Using a highly sensitive (97%) and speci¢c (98%)
enzyme-linked immunosorbent assay (ELISA) (Warren et al,
2000), 30 of 31 patients had detectable IgG antibodies to dsg1.
We also identi¢ed IgG antibodies to dsg1 in 55% of normal sub-
jects living in this endemic focus, and at lower levels in normal
subjects living in nearby areas. Antibodies to dsg1 were also
detected in patients with endemic pemphigus up to 4 y before
the onset of clinical disease, with a marked increase in antibodies
to dsg1 (as measured in an ELISA for total IgG) associated with
onset of clinical disease. An environmental trigger factor has been
proposed to explain these and other ¢ndings (Diaz et al, 1989b;
Hans-Filho et al, 1996;Warren et al, 2000).These ¢ndings also raise
the issue of why the normal subjects with antibodies to dsg1 did
not develop clinical disease.
In this study we therefore sought to determine if patients
and normal subjects di¡er in terms of their IgG subclass response
to dsg1.
METHODS
Sources of sera We obtained sera from all 31 patients with endemic
pemphigus foliaceus in Limao Verde, Brazil. For ¢ve patients we also
obtained serum samples from before the onset of clinical disease. The
patients consisted of 13 women and 18 men. Their age range was 7^71 y,
with a mean age of 36 y. The diagnosis of endemic pemphigus was made
by a dermatologist on the basis of clinical examination, biopsy, direct
immuno£uorescence, and indirect immuno£uorescence. We also selected
serum samples from 31 normal subjects living in Limao Verde from a
larger group of 93 that were previously tested (Warren et al, 2000) who
had a strong total IgG antibody response to dsg1. They were of
comparable age and sex to the patients, with 13 women and 18 men. The
age range was 5^85 y and the mean age was 38 y.We also selected serum
samples from 10 normal subjects living in LimaoVerde who had previously
been identi¢ed as having undetectable levels of antibodies to dsg1, and 41
normal subjects from the U.S.A. The latter were randomly selected healthy
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blood donors, identi¢ed only by a code. All normal subjects from Brazil
were examined by a dermatologist at the time of blood drawing. Blood
samples from Limao Verde were shipped to the nearby city of Campo
Grande, where the serum was separated and stored at ^201C. The samples
were shipped frozen to the U.S.A. where all immunologic testing was
done. The study had the approval of FUNAI, a body representing the
interests of the Indians of LimaoVerde, as well as institutional approval of
the University of North Carolina, Chapel Hill.
ELISA The complete extracellular domain of dsg1 was produced in the
baculovirus system (Ding et al, 1997). A polyhistidine tag at the carboxy end
enabled puri¢cation on a nickel-NTA a⁄nity column (Qiagen,
Chatsworth, CA). Protein was eluted from the column with 150 mM
imidazole in Tris-bu¡ered saline with calcium (TBS-Ca2þ ), pH 8.0. The
imidazole was removed by dialysis against TBS-Ca2þ pH 7.2 for 48 h
using 25 kDa cellulose ester dialysis bags (Spectrum, Houston,TX, USA).
The presence of the 66 kDa extracellular domain was con¢rmed by
immunoblot assay using rabbit antidsg1 antibodies. The average yield of
protein was 20 mg per ml of crude supernatant.
Dsg1 inTBS-Ca2þ , 0.2% bovine serum albumin (BSA) was coated onto
nickel-NTA ELISA plates (Qiagen) at 1.1 mg per well and incubated
overnight at 41C. Plates were washed ¢ve times with TBS-Ca2þ pH 7.2,
0.05% Tween-20, and the patient or normal subject sera were added in
duplicate at a dilution of 1:50 in TBS-Ca2þ , 0.05%Tween, 0.2% BSA.
Wells were incubated for 1h and washed as above. Each serum sample
was incubated with horseradish-peroxidase-conjugated mouse monoclonal
antibody speci¢c for human IgG1, IgG2, IgG3, and IgG4 (Zymed
Laboratories, San Francisco, CA), for 1 h. Following a wash step, 200 ml of
O-phenylenediamine in phosphatecitrateperborate bu¡er (Sigma, St.
Louis MO) was added for color development and 2 N H2SO4 was used
to stop the reaction after 10min.The optical density (OD) was read at 492
nm using an ELISA plate reader (Biorad, Hercules, CA).
The dilutions of the secondary antibodies were determined as follows.
Elisa plates were coated for 1 h with 14 ng of puri¢ed IgG1, IgG2, IgG3,
and IgG4 (Sigma) in bicarbonate bu¡er pH 9.6. Plates were blocked
with 0.2% BSA (Sigma) in phosphate-bu¡ered saline (PBS) and washed
in PBS, 0.05% Tween-20, and the horseradish-peroxidase-conjugated
monoclonal mouse antihuman IgG subclass antibodies (Zymed) were
added. The dilutions of the secondary antibodies were adjusted so that
each gave the same OD result with its own subclass standard.
The same positive and negative controls were used in duplicate on every
ELISA plate, and incubated with all four secondary antibodies on every
plate.
Statistics Duplicate ELISA results were averaged. A cut-o¡ value for
each subclass ELISA was established as a value 3 SD above the mean of
the 41 normal donors from the U.S.A. Several sera generated negative
values after subtraction of background and correction for plate-to-plate
variability, as their OD value was below the negative control. An ELISA
index value for each subclass was obtained for each patient or normal
subject as follows: (mean test resultmean subclass negative control)C
(mean subclass positive controlmean subclass negative control) subclass
correction factor100.
The subclass correction factor was determined for each subclass as the
mean of all the positive controls for that subclass on all plates minus the
mean of the negative controls, divided by the cut-o¡ for that subclass
assay. The reason for the use of this correction factor was to maintain the
comparability of the di¡erent subclass results to each other. As a result, any
index value over 1was considered positive. Groups of patients and normal
subjects were compared using the Van der Waerden nonparametric
procedure. For comparing patients before and after the onset of disease,
the sine rank test was used.
RESULTS
Characterization of the dsg1 subclass ELISA assays We
tested 41 normal donors from the U.S.A. One control serum
out of 41 fell just above the cut-o¡ for the IgG2 and IgG4 assays,
with values of 1.44 and 1.003, respectively. Two control sera
fell just above the cut-o¡ for IgG1, with values of 1.29 and 1.27.
No sera fell above the cut-o¡ for the IgG3 assay. Speci¢city for
the assays was therefore as follows: IgG1 was 95%, IgG2 was
97.5%, IgG3 was 100%, and IgG4 was 97.5%. To con¢rm the
speci¢city of each monoclonal secondary antibody for its own
immunoglobulin subclass, plates were coated with standard
concentrations of all four puri¢ed IgG subclasses. Each subclass
assay was tested on plates coated with its own puri¢ed
immunoglobulin subclass and all the others. No cross-reactivity
was seen. The mean OD value for wells in which reactivity was
expected was 1.47, whereas the mean OD value for wells in which
no reactivity was expected was 0.016. Antibodies were detected in
28 of 31 patients in one or more subclasses, giving the assay a
sensitivity of 90%. All three patients with a negative test were
in clinical remission at the time of testing.
IgG subclass response to dsg1 in patients with endemic
pemphigus foliaceus We tested all 31 patients with endemic
pemphigus in Limao Verde. The humoral immune response was
predominantly IgG1 and IgG4 (see Fig 1, gray bars). We detected
IgG1 subclass antibodies to dsg1 in 25 of 31 patients (mean index
value 5.99), and IgG4 subclass antibodies in 24 out of 31 (mean
index value 111.42). The mean index value for IgG2 was just
above the cut-o¡ (1.62 units) and the mean value for IgG3 was
just below the cut-o¡ (0.16 units).
IgG subclass response to dsg1 in normal subjects living in
the endemic area We tested 31 normal subjects from Limao
Verde who had previously been identi¢ed (Warren et al, 2000) to
have a high level of IgG antibodies to dsg1 by ELISA and
immunoprecipitation (see Fig 1, black bars). We detected IgG1
subclass antibodies to dsg1 in 28 of 31 normal subjects, with a
mean index value of 5.84. This was not signi¢cantly di¡erent
from IgG1 in the patients (mean index value 5.99, p¼ 0.53). We
detected low levels of IgG4 subclass antibodies to dsg1 in 17 of
31 normal subjects. The mean index value was 5.76, which was
19.3-fold lower than the mean index value in the patients (index
value 111.42). Patients and normal subjects were signi¢cantly
di¡erent in the IgG4 assay (p¼ 0.004). The mean index values
for IgG2 and IgG3 were both below the cut-o¡ (mean index
values 0.79, 0.09, respectively) and there were no signi¢cant
di¡erences between the patients and normal subjects (p¼ 0.18
for IgG2, p¼ 0.83 for IgG3).We also tested a separate group of 10
normal subjects from Limao Verde who had previously been
identi¢ed to have no IgG antibodies to dsg1 by ELISA and
Figure1. Mean IgG subclass values in 31 patients and 31 ELISA-po-
sitive normal subjects from Limao Verde. Antibodies to dsg1 in each
subclass were measured by ELISA. Each assay was standardized so as to
enable comparability between subclasses. A group of 41 normal subjects
from the U.S.A. was used to determine the normal ranges for each subclass
(see Methods). All 31 patients in LimaoVerde (gray bars) were compared to a
group of 31 age and sex matched normal subjects (black bars) from the en-
demic area whowere previously con¢rmed to have an antibody response to
dsg1. Bars indicate mean7SEM.
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immunoprecipitation (Warren et al, 2000). No antibodies in any
IgG subclass were detected except for two normal subjects whose
IgG4 OD value was just above the cut-o¡ (index values 2.19 and
1.77) (data not shown).
Levels of IgG4 correlate closely with disease activity and
remission Information about the presence of active disease or
remission at the time of the blood sample was available for all
patients. The level of IgG4 correlated closely with disease
activity and remission. A positive IgG4 test was associated with
active disease in 22 out of 23 patients. A negative IgG4 test was
associated with remission in six of eight patients. These
correlations were not seen with IgG1, which was positive in
active disease in 20 of 23 patients but also remained positive in
remission in ¢ve of eight patients. Mean levels of IgG4 (Fig 2)
were 74.3-fold higher in patients with active disease (index value
149.47) than in those in remission (mean index value 2.01), and
these di¡erences were signi¢cantly di¡erent (p¼ 0.0006). This
marked trend was not seen with IgG1 where the mean value in
active disease was 7.01 and the mean value in remission was 3.08,
giving a 2.2-fold increase associated with active disease. The
di¡erence in IgG1was not signi¢cant at the 5% level (p¼ 0.086).
There was also a signi¢cant di¡erence between remission and
active disease for IgG2 (p¼ 0.009). Only 11 of 23 patients with
active disease had a weakly positive IgG2 response, however, and
the mean IgG2 response was only just above the cut-o¡ (2.04). For
IgG3 there was again a statistically signi¢cant di¡erence between
active disease and remission (p¼ 0.024); however, only one
patient with active disease had a weak positive result (1.18), and
the mean values were below the cut-o¡ for both active disease
and remission.
In ¢ve patients with endemic pemphigus, fromwhom blood
samples were available before and after the onset of clinical
disease, a marked rise in antidsg1 antibodies of IgG4 subclass
was observed with onset of the disease We tested ¢ve
patients from Limao Verde from whom blood samples were
available from 1 to 4 y before the onset of clinical disease, as
well as after the onset of clinical disease (Fig 3). In three of ¢ve,
anti-dsg-1 antibodies of IgG1 subclass were detectable 1^4 y before
the onset of the disease. Onset of the disease was associated with a
mean increase in IgG1 OD value of 3.45-fold (p¼ 0.15). In
contrast IgG4 antibodies were detectable in only two of ¢ve
before the onset of disease, and there was a marked rise in levels
of IgG4 antibodies in four of ¢ve patients with a mean 103.08-
fold rise in ELISAvalue for IgG4 after onset of disease (p¼ 0.03).
DISCUSSION
It has been well documented that patients with pemphigus have
a pathogenic antibody response to dsg1 (Rock et al, 1989; Amagai
et al, 1995; Ding et al, 1999).We have previously shown that anti-
bodies to dsg1 are also detectable in normal subjects living in the
endemic area, and in patients 1^4 y before the onset of clinical
disease (Warren et al, 2000). In this study we show that normal
subjects and patients from LimaoVerde di¡er mainly in terms of
their IgG4 subclass response to dsg1 (Fig 1). Patients in remission
di¡er from patients with active disease mainly in terms of their
IgG4 response (Fig 2). In the ¢ve patients from whom we had
blood samples both before and after the onset of clinical disease
(Fig 3), the immune response before onset of disease again di¡ers
from that after onset of disease mainly in terms of IgG4.
These results suggest that progression from a preclinical to a
clinical phase of the disease, and also the transition from disease
in remission to active disease, is closely associated with subclass
switching from IgG1 to IgG4. These results also suggest that anti-
bodies to dsg1 of IgG1 subclass alone are incapable of triggering
disease. Preliminary studies (Lin et al, unpublished observations)
suggest that IgG1 subclass antibodies from a normal subject who
has only an IgG1 response are incapable of mediating disease at 15
mg per kg in the mouse passive transfer model. In contrast IgG4
antibodies from a patient were capable of mediating disease at
1.5 mg per kg, a concentration 10 times lower.
This study raises the issue of susceptibility genes for pemphi-
gus. If we assume that both patients and normal subjects living i
n the endemic area are exposed to the putative environmental
trigger (Robledo et al, 1988; Diaz et al, 1989b;Warren et al, 2000),
Figure 2. Mean IgG subclass values for eight patients in remission
and 23 patients with active disease. Patients with endemic pemphigus
were divided into a group of eight in clinical remission (black bars) and 23
with active disease (gray bars) and assayed using the subclass ELISA for re-
activity to dsg1. Bars indicate mean7SEM.
Figure 3. IgG subclass values in ¢ve patients before and after the on-
set of clinical disease. In ¢ve patients (numbered 1^5) blood samples were
available up to 4 y before the onset of clinical disease, as well as after the
onset of clinical disease. Levels of antibodies to dsg1 in the IgG subclasses
were compared both before (black bars) and after (gray bars) the onset of clin-
ical disease, using the subclass ELISA for dsg1.
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possibly patients are able to make a much stronger pathogenic
IgG4 response because of the presence of susceptibility gene(s).
HLA susceptibility genes for endemic pemphigus have already
been identi¢ed in Limao Verde and elsewhere in Brazil, namely
HLA DRB1-0102, 0404, 1402 (Moraes et al, 1991; Cerna et al, 1993;
Moraes et al, 1997). These alleles all share a consensus sequence
LLEQRRAA at position 67^74 in the third hypervariable do-
main of the DRB1 gene. These alleles confer a high relative risk
of disease and are seen at lower levels in normal subjects from
endemic areas (Moraes et al, 1997). It is possible that exposure to
the unknown environmental trigger is enough for over half of
those living in the endemic area to produce a nonpathogenic
antibody response (Warren et al, 2000). The HLA susceptibility
alleles would then be required for production of a pathogenic
IgG4 response and the development of disease. Circumstantial
support for this model comes from the ¢nding that the ELISA-
positive normal subjects do not have an increase above the popu-
lation level in the HLA susceptibility alleles (Diaz,Warren et al,
unpublished), suggesting that the susceptibility alleles are not in-
volved in the production of the initial, nonpathogenic antibody
response, but rather play a role in the transition to a pathogenic
antibody response.
Additional support for this model comes from the animal
models of myasthenia gravis and multiple sclerosis (Piddlesden
et al, 1993; Karachunski et al, 1995; Drachman et al, 1998; Yang
et al, 1998; Ichikawa et al, 1999). Drachman et al (1998) and Yang
et al (1998) immunized two groups of congenic mice with puri-
¢ed acetylcholine receptor. The two groups of mice di¡er only
in a three amino acid portion of the MHC I-A^b. One group is
capable of producing a pathogenic antibody response of subclass
IgG2b resulting in clinical disease, whereas the other group pro-
duces a nonpathogenic antibody response without accentuation
of IgG2b subclass, and does not develop clinical disease. Interest-
ingly the two groups of mice also responded to di¡erent epitopes
on the acetylcholine receptor. Ichikawa et al (1999) immunized
NOD mice with myelin oligodendrocyte protein, and identi¢ed
a subgroup with a severe multiple-sclerosis-like disease and a
subgroup with mild or no disease. Both subgroups had an anti-
body response to myelin oligodendrocyte protein, and mean
total IgG against myelin oligodendrocyte protein was similar in
the two subgroups; however, the subgroup with severe disease
had a predominantly IgG2b response that was not seen in the
other subgroup.
Similar ¢ndings have also been recorded in pemphigus vul-
garis (Jones et al, 1988; Bhol et al, 1994; Hertl and Riechers, 1999;
Kricheli et al, 2000). Kricheli et al (2000) identi¢ed antibodies to
dsg3 in the serum of 91% of patients by immunoblot, and also in
49% of those related to patients.The distribution of IgG1 through
IgG3 was similar in patients and relatives. IgG4 was seen in 62%
of the patients but fewer than 2% of the relatives and none of the
normal subjects. Bhol et al (1994), using an immunoblot assay,
found a predominantly IgG1 response to dsg3 in relatives of pa-
tients and patients in remission, with patients with clinical disease
having an IgG1 and IgG4 response. Our group has previously
identi¢ed IgG4 as being the predominant antibody subclass in en-
demic pemphigus foliaceus, and also capable of reproducing the
disease after passive transfer into mice (Rock et al, 1989). In addi-
tion IgG1 has been detected early in the course of clinical disease,
with IgG4 being detected throughout the course of clinical dis-
ease (dos Santos, 1996). This study is the ¢rst to elucidate the dif-
ference between the antibody response in normal subjects living
in an endemic area and patients, the role of subclass switching in
the pathogenesis of the disease, and the association of IgG sub-
classes with active disease versus remission.
Our study leaves open the possibility that the pathogenic IgG4
antibodies recognize a di¡erent epitope to the nonpathogenic
IgG1 antibodies. This issue may be amenable to study using do-
main-swapped molecules. Alternatively IgG4 may have a still un-
known e¡ector function that is not present in IgG1, or a higher in
vivo binding a⁄nity for dsg1. IgG4 is not thought to activate
complement: previous studies (Rock et al, 1990; Espana et al,
1997) have suggested that complement is not essential for blister
formation, and that antibodies to dsg1may cause blisters by bind-
ing to dsg1 rather than by activating proteolytic enzymes or an
in£ammatory cascade. Nevertheless components of complement
are usually deposited in lesional biopsies and pemphigus foliaceus
sera have been shown to be capable of activating complement
(Hashimoto et al, 1982; Kawana et al, 1988).
This study also makes it possible to identify a subgroup of nor-
mal subjects, namely those with a raised level of IgG4 antibodies
to dsg1, who may be at a higher risk of developing clinical dis-
ease. In addition these results suggest that the level of IgG4 as
measured in a subclass ELISA may be the most sensitive indicator
of clinical activity in patients with endemic pemphigus, and pos-
sibly in other related forms of pemphigus. In conclusion, the dsg1
subclass ELISA should prove to be a powerful tool in dissecting
stages in the pathogenesis of this autoimmune disease.
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